Human MC5R Stable Cell Line - HEK293

The MC5R gene, also known as the melanocortin 5 receptor gene, encodes a G protein-coupled receptor (GPCR) belonging to the melanocortin receptor family. This receptor is primarily activated by melanocortin peptides, such as α-melanocyte-stimulating hormone (α-MSH), β-melanocyte-stimulating hormone (β-MSH), and adrenocorticotropic hormone (ACTH). MC5R is widely expressed in various peripheral tissues, including the skin, exocrine glands (such as sebaceous and sweat glands), adipose tissue, and immune cells. Its biological functions are diverse, encompassing regulation of exocrine gland secretion, immune responses, inflammation, and energy homeostasis. Studies have shown that MC5R plays a crucial role in sebum secretion, thermoregulation, and pheromone signaling. Mutations or dysregulation of MC5R are closely associated with diseases such as obesity, metabolic disorders, and skin diseases, making it an important therapeutic research target in the fields of endocrinology and dermatology.

The HEK293 cell line, a stable human MC5R cell line, is a genetically engineered cell line designed for stable and reliable studies of the MC5R receptor in a controlled laboratory environment. Derived from HEK293 cells (human embryonic kidney cells), this cell line is genetically modified to stably express the human MC5R gene. HEK293 cells are the preferred cell line for such applications due to their high transfection efficiency, vigorous growth, and compatibility with various biochemical analysis methods. Stable expression of MC5R ensures long-term receptor availability without the need for repeated transfections, thus contributing to the reproducibility of experiments such as drug discovery, receptor pharmacology, and signal transduction studies. Researchers use this cell line to study ligand-receptor interactions, screen agonists or antagonists, assess downstream signaling pathways (e.g., cAMP accumulation), and evaluate receptor internalization or desensitization. Its applications also include high-throughput screening (HTS) of drug candidates for MC5R-related diseases (e.g., metabolic syndrome or inflammatory diseases).